Welcome to LookChem.com Sign In|Join Free

CAS

  • or

934665-56-2

Post Buying Request

934665-56-2 Suppliers

Recommended suppliersmore

  • Product
  • FOB Price
  • Min.Order
  • Supply Ability
  • Supplier
  • Contact Supplier
  • 1-Piperidinecarboxylic acid, 2-[1-[3,4-difluoro-2-[(2-fluoro-4-iodophenyl)aMino]benzoyl]-3-hydroxy-3-azetidinyl]-, 1,1-diMethylethyl ester, (2R)-

    Cas No: 934665-56-2

  • No Data

  • No Data

  • No Data

  • Hangzhou Dingyan Chem Co., Ltd
  • Contact Supplier
  • tert-butyl (R)-2-(1-(3,4-difluoro-2-((2-fluoro-4-iodophenyl)amino)benzoyl)-3-hydroxyazetidin-3-yl)piperidine-1-carboxylate

    Cas No: 934665-56-2

  • No Data

  • No Data

  • No Data

  • Chemlyte Solutions
  • Contact Supplier
  • 1-Piperidinecarboxylic acid, 2-[1-[3,4-difluoro-2-[(2-fluoro-4-iodophenyl)aMino]benzoyl]-3-hydroxy-3-azetidinyl]-, 1,1-diMethylethyl ester, (2R)-

    Cas No: 934665-56-2

  • No Data

  • No Data

  • No Data

  • ZHEJIANG JIUZHOU CHEM CO.,LTD
  • Contact Supplier
  • 1-Piperidinecarboxylic acid, 2-[1-[3,4-difluoro-2-[(2-fluoro-4-iodophenyl)aMino]benzoyl]-3-hydroxy-3-azetidinyl]-, 1,1-diMethylethyl ester, (2R)-

    Cas No: 934665-56-2

  • No Data

  • No Data

  • No Data

  • GZ HONESTCHEM CO., LTD
  • Contact Supplier

934665-56-2 Usage

General Description

The chemical "1-Piperidinecarboxylic acid, 2-[1-[3,4-difluoro-2-[(2-fluoro-4-iodophenyl)aMino]benzoyl]-3-hydroxy-3-azetidinyl]-, 1,1-diMethylethyl ester, (2R)-" is a complex organic compound. It is a piperidinecarboxylic acid derivative, with a 2R stereoisomer configuration. It contains a 2-[1-[3,4-difluoro-2-[(2-fluoro-4-iodophenyl)aMino]benzoyl]-3-hydroxy-3-azetidinyl]- side chain, and is esterified with 1,1-diMethylethyl. 1-Piperidinecarboxylic acid, 2-[1-[3,4-difluoro-2-[(2-fluoro-4-iodophenyl)aMino]benzoyl]-3-hydroxy-3-azetidinyl]-, 1,1-diMethylethyl ester, (2R)- may have potential pharmaceutical applications, but its precise uses and effects would need to be determined through further research and testing.

Check Digit Verification of cas no

The CAS Registry Mumber 934665-56-2 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 9,3,4,6,6 and 5 respectively; the second part has 2 digits, 5 and 6 respectively.
Calculate Digit Verification of CAS Registry Number 934665-56:
(8*9)+(7*3)+(6*4)+(5*6)+(4*6)+(3*5)+(2*5)+(1*6)=202
202 % 10 = 2
So 934665-56-2 is a valid CAS Registry Number.

934665-56-2Downstream Products

934665-56-2Relevant articles and documents

PROCESS FOR THE PRODUCTION OF COBIMETINIB

-

, (2019/05/22)

The present invention relates to a novel route of synthesis for the production of enantiomerically pure Cobimetinib, new intermediates in the synthesis of Cobimetinib and an amorphous Cobimetinib hemifumarate salt comprising a high salt content.

A 3 - (piperidin - 2 - yl) - azetidine - 3 - ol derivatives of synthetic method and use thereof

-

, (2017/12/05)

The invention discloses a synthesis method of 3-(piperidyl-2-yl)-azetidinyl-3-ol derivatives and a method for synthesizing Cobimetinib from the compounds. The method comprises the following steps: by using compounds F as an initial raw material, carrying

Novel carboxamide-based allosteric MEK inhibitors: Discovery and optimization efforts toward XL518 (GDC-0973)

Rice, Kenneth D.,Aay, Naing,Anand, Neel K.,Blazey, Charles M.,Bowles, Owen J.,Bussenius, Joerg,Costanzo, Simona,Curtis, Jeffry K.,Defina, Steven C.,Dubenko, Larisa,Engst, Stefan,Joshi, Anagha A.,Kennedy, Abigail R.,Kim, Angie I.,Koltun, Elena S.,Lougheed, Julie C.,Manalo, Jean-Claire L.,Martini, Jean-Francois,Nuss, John M.,Peto, Csaba J.,Tsang, Tsze H.,Yu, Peiwen,Johnston, Stuart

, p. 416 - 421 (2012/06/30)

The ERK/MAP kinase cascade is a key mechanism subject to dysregulation in cancer and is constitutively activated or highly upregulated in many tumor types. Mutations associated with upstream pathway components RAS and Raf occur frequently and contribute to the oncogenic phenotype through activation of MEK and then ERK. Inhibitors of MEK have been shown to effectively block upregulated ERK/MAPK signaling in a range of cancer cell lines and have further demonstrated early evidence of efficacy in the clinic for the treatment of cancer. Guided by structural insight, a strategy aimed at the identification of an optimal diphenylamine-based MEK inhibitor with an improved metabolism and safety profile versus PD-0325901 led to the discovery of development candidate 1-({3,4-difluoro-2-[(2-fluoro-4-iodophenyl)amino]phenyl}carbonyl)-3-[(2S) -piperidin-2-yl]azetidin-3-ol (XL518, GDC-0973) (1). XL518 exhibits robust in vitro and in vivo potency and efficacy in preclinical models with sustained duration of action and is currently in early stage clinical trials.

Post a RFQ

Enter 15 to 2000 letters.Word count: 0 letters

Attach files(File Format: Jpeg, Jpg, Gif, Png, PDF, PPT, Zip, Rar,Word or Excel Maximum File Size: 3MB)

1

What can I do for you?
Get Best Price

Get Best Price for 934665-56-2